Dronedarone: An overview

References

• Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, . ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8:651–745.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Banach M. Atrial fibrillation: the new epidemic of the ageing world. J Atrial Fibrillation. 2009;1:337–61.
   Google Scholar
• Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at ‘moderate risk’ [CHADS2 score = 1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost. 2010;103:683–5.
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, . A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.
   PubMed Web of Science ®Google Scholar
• Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, . A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–40.
   PubMed Web of Science ®Google Scholar
• Freudenberger RS, Wilson AC, Kostis JB; AFFIRM Investigators and Committees. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J Cardiol. 2007;100:247–52.
   PubMed Web of Science ®Google Scholar
• Guglin M, Chen R, Curtis AB. Sinus rhythm is associated with fewer heart failure symptoms: insights from the AFFIRM trial. Heart Rhythm. 2010;7:596–601.
   PubMedGoogle Scholar
• Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, . Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509–13.
   PubMed Web of Science ®Google Scholar
• Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, . Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324:781–8.
   PubMed Web of Science ®Google Scholar
• Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719–28.
   PubMed Web of Science ®Google Scholar
• Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, . ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8:746–837.
   PubMed Web of Science ®Google Scholar
• Kozlowski D, Budrejko S, Lip GYH, Mikhailidis DP, Rysz J, Raczak G, . Vernakalant hydrochloride for the treatment of atrial fibrillation. Expert Opin Investig Drugs. 2009;18:1929–37.
   PubMed Web of Science ®Google Scholar
• Kowalczyk M, Banach M, Lip GYH, Kozłowski D, Mikhailidis DP, Rysz J. Levosimendan—a calcium sensitising agent with potential anti-arrhythmic properties. Int J Clin Pract. 2010;64:1148–54.
   PubMedGoogle Scholar
• Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, . Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357:987–99.
   PubMed Web of Science ®Google Scholar
• Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24:1481–7.
   PubMed Web of Science ®Google Scholar
• Dronedarone: drondarone, SR 33589, SR 33589B. Drugs R D. 2007;8:171–5.
   PubMedGoogle Scholar
• Hodeige D, Heyndrickx JP, Chatelain P, Manning A. SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Eur J Pharmacol. 1995;279:25–32.
   PubMed Web of Science ®Google Scholar
• Zareba KM. Dronedarone: a new antiarrhythmic agent. Drugs Today (Barc). 2006;42:75–86.
   PubMed Web of Science ®Google Scholar
• Doggrell SA, Hancox JC. Dronedarone: an amiodarone analogue. Expert Opin Investig Drugs. 2004;13:415–26.
   PubMed Web of Science ®Google Scholar
• Chatelain P, Meysmans L, Matteazzi JR, Beaufort P, Clinet M. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol. 1995;116:1949–56.
   PubMed Web of Science ®Google Scholar
• Finance O, Manning A, Chatelain P. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol. 1995;26:570–6.
   PubMed Web of Science ®Google Scholar
• Cheng TO. This DAFNE is definitely not that DAFNE. Int J Cardiol. 2005;101:323.
   PubMedGoogle Scholar
• Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, . Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358:2678–87.
   PubMed Web of Science ®Google Scholar
• Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C, . Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007;64: 785–91.
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, . Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009; 360:668–78.
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, . Dronedarone in patients with congestive heart failure: insights from ATHENA. Eur Heart J. 2010;31:1717–21.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, . Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120:1174–80.
   PubMed Web of Science ®Google Scholar
• Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D, . Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156: 527.e1–9.
   PubMed Web of Science ®Google Scholar
• Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS Study. J Cardiovasc Electrophysiol. 2010;21:597–605.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009;54: 1089–95.
   PubMed Web of Science ®Google Scholar
• Varro A, Takacs J, Nemeth M, Hala O, Virag L, Iost N, . Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol. 2001;133: 625–34.
   PubMed Web of Science ®Google Scholar
• Manning A, Thisse V, Hodeige D, Richard J, Heyndrickx JP, Chatelain P. SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs. J Cardiovasc Pharmacol. 1995;25:252–61.
   PubMed Web of Science ®Google Scholar
• Cooper JA. Dronedarone is superior to placebo the case for optimism. J Am Coll Cardiol. 2010;55:1052.
   PubMedGoogle Scholar
• Lewalter T. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2010;55: 1051–2.
   PubMedGoogle Scholar
• Sherman DG, Kim SG, Boop BS, Corley SD, Dimarco JP, Hart RG, . Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med. 2005;165:1185–91.
   PubMed Web of Science ®Google Scholar
• Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, . Postoperative atrial fibrillation—what do we really know? Curr Vasc Pharmacol. 2010;8:553–72.
   PubMed Web of Science ®Google Scholar
• Duray GZ, Schmitt J, Hohnloser SH. Dronedarone therapy in atrial fibrillation: A summary of recent controlled trials. J Cardiovasc Pharmacol Ther. 2010;15(4 Suppl):19S–23S.
   Google Scholar
• Gautier P, Guillemare E, Marion A, Bertrand JP, Tourneur Y, Nisato D. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol. 2003;41:191–202.
   PubMed Web of Science ®Google Scholar
• Guillemare E, Marion A, Nisato D, Gautier P. Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells. J Cardiovasc Pharmacol. 2000;36:802–5.
   PubMed Web of Science ®Google Scholar
• Burashnikov A, Belardinelli L, Antzelevitch C. Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. Heart Rhythm. 2010;7:1273–9.
   PubMed Web of Science ®Google Scholar
• Aimond F, Beck L, Gautier P, Cherif OK, Davy JM, Lorente P, . Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats. J Pharmacol Exp Ther. 2000;292:415–24.
   PubMed Web of Science ®Google Scholar
• Manning AS, Bruyninckx C, Ramboux J, Chatelain P. SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. J Cardiovasc Pharmacol. 1995;26:453–61.
   PubMed Web of Science ®Google Scholar
• Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation. 1999;100:2276–81.
   PubMed Web of Science ®Google Scholar